Chronic recurrent multifocal osteomyelitis (CRMO) is a rare condition (1:1,000,000), in which the bones have lesions, inflammation, and pain.

Symptoms may include bone and joint pain, skin redness or inflammation, inflammatory bowel disease, psoriasis, and blister-like lesions on the palms and soles of the feet.

[1] Some specialists believe they have discovered a link between CRMO with a rare allele of marker D18S60, resulting in a haplotype relative risk (HRR) of 18.

[citation needed] Due to its inflammatory nature, its recurrent flares, and its lack of any known pathogen, CRMO has been reclassified as an autoinflammatory disease.

[citation needed] First line treatments include[citation needed] Naproxen (Aleve), Celecoxib (Celebrex) Meloxicam (Mobic), Piroxicam (Feldene), Indomethacin (Indocin), Diclofenac (Voltaren) Second line treatments include corticosteroids (Prednisone/Prednisolone), Methotrexate (Otrexup, Rasuvo, Trexall), Sulfasalazine (Azulfidine), Pamidronate (Aredia), Zoledronic acid (Zometa), Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade)[citation needed] These medications are also used in children with other inflammatory and/or bone conditions.

[citation needed] Majeed syndrome is an autoinflammatory disorder consisting of CRMO, congenital dyserythropoietic anemia, and neutrophilic dermatosis.

In addition, bone marrow aspiration demonstrated significant dyserythropoiesis (defective red cell formation), suggesting Majeed syndrome.

[3] Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis, uncommon childhood diseases of unknown cause, occurred in three children (two brothers and a female cousin).

The association of Sweet syndrome with chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anemia in this family suggests that these rare conditions may be interrelated.